Publications from Clinical Cancer Research Unit (CRU)

Publications 2025

Ascierto PA, Tang H, Dolfi S, Nyakas M, Marie Svane I, Muñoz-Couselo E, Grob JJ, Gomez-Roca CA, Chiarion-Sileni V, Peltola K, Larkin J, Melero I, Callahan M, Dummer R, Djidel P, Warad D, Reusser-Wolf D, Lipson EJ, Garnett-Benson C (2025)
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
J Immunother Cancer, 13 (2)
DOI 10.1136/jitc-2024-009773, PubMed 40010775

Kolstad A, Emanuel G, Hjortland GO, Nilssen Y, Ulvestad M, Areffard A, Aahlin EK (2025)
Long-term trends in the clinical management and outcomes of patients with gastroesophageal cancer in Norway
Acta Oncol, 64, 540-549
DOI 10.2340/1651-226X.2025.43167, PubMed 40235057

Pati NB, Jin Y, Kumar S, Kyte JA, Ciosk R (2025)
Thermal potentiation improves IFN-γ production but not cytotoxicity in human CAR-T cells
BMC Res Notes, 18 (1), 192
DOI 10.1186/s13104-025-07249-5, PubMed 40270044

Publications 2024

Andresen NK, Røssevold AH, Borgen E, Schirmer CB, Gilje B, Garred Ø, Lømo J, Stensland M, Nordgård O, Falk RS, Mathiesen RR, Russnes HG, Kyte JA, Naume B (2024)
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials
Mol Oncol (in press)
DOI 10.1002/1878-0261.13675, PubMed 38978352

Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA (2024)
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
J Immunother Cancer, 12 (1)
DOI 10.1136/jitc-2023-007990, PubMed 38242720

Bjerring AW, Smeland KH, Stokke T, Haugaa KH, Holte E, Rösner A, Kiserud CE, Edvardsen T, Sarvari SI (2024)
Long-term cardiac effects of modern treatment for Hodgkin's lymphoma
Cardiooncology, 10 (1), 19
DOI 10.1186/s40959-024-00222-4, PubMed 38576044

Chauhan SK, Dunn C, Andresen NK, Røssevold AH, Skorstad G, Sike A, Gilje B, Raj SX, Huse K, Naume B, Kyte JA (2024)
Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation
NPJ Breast Cancer, 10 (1), 30
DOI 10.1038/s41523-024-00638-2, PubMed 38653982

Dahl AA, Smeland KB, Eikeland S, Fagerli UM, Bersvendsen HS, Fosså A, Kiserud CE (2024)
Distressed personality is associated with late adverse effects in long-term survivors of Hodgkin lymphoma
Acta Oncol, 63, 600-606
DOI 10.2340/1651-226X.2024.40312, PubMed 39099321

Elvebakken H, Venizelos A, Perren A, Couvelard A, Lothe IMB, Hjortland GO, Myklebust TÅ, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Vestermark LW, Knappskog S, Sorbye H (2024)
Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms
Br J Cancer, 131 (4), 676-684
DOI 10.1038/s41416-024-02773-w, PubMed 38909137

Grivas P, Garralda E, Meric-Bernstam F, Mellinghoff IK, Goyal L, Harding JJ, Dees EC, Bahleda R, Azad NS, Karippot A, Kurzrock R, Tabernero J, Kononen J, Ng MCH, Mehta R, Uboha NV, Bigot F, Boni V, Bowyer SE, Breder V, Cervantes A, Chan N, Cleary JM, Dhawan M, Eefsen RL et al. (2024)
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Clin Cancer Res, 30 (20), 4572-4583
DOI 10.1158/1078-0432.CCR-24-0012, PubMed 38771739

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjærde OC, Tveit KM, Spindler KG, Pallisgaard N, Kure EH (2024)
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
Clin Colorectal Cancer (in press)
DOI 10.1016/j.clcc.2024.11.004, PubMed 39743478

Jin Y, Dunn C, Persiconi I, Sike A, Skorstad G, Beck C, Kyte JA (2024)
Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers
Int J Mol Sci, 25 (1)
DOI 10.3390/ijms25010586, PubMed 38203757

Jin Y, Dunn C, Persiconi I, Sike A, Skorstad G, Beck C, Kyte JA (2024)
Correction: Jin et al. Comparative Evaluation of STEAP1 Targeting Chimeric Antigen Receptors with Different Costimulatory Domains and Spacers. Int. J. Mol. Sci. 2024, 25, 586
Int J Mol Sci, 25 (18)
DOI 10.3390/ijms251810024, PubMed 39337718

Lereim RR, Dunn C, Aamdal E, Chauhan SK, Straume O, Guren TK, Kyte JA (2024)
Plasma protein dynamics during ipilimumab treatment in metastatic melanoma: associations with tumor response, adverse events and survival
Oncoimmunology, 14 (1), 2440967
DOI 10.1080/2162402X.2024.2440967, PubMed 39703053

Long GV, Carlino MS, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance AM, Daud AI, Hamid O, Larkin J, Yao L, Singh R, Lal R, Robert C (2024)
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
Ann Oncol, 35 (12), 1191-1199
DOI 10.1016/j.annonc.2024.08.2330, PubMed 39306585

Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, Merelli B, Sileni VC, Nyakas M, Haydon A, Dutriaux C, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Larkin J, Tan M, Adnaik SB, Burgess P, Jandoo T, Dummer R (2024)
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
N Engl J Med, 391 (18), 1709-1720
DOI 10.1056/NEJMoa2404139, PubMed 38899716

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, Helland Å, InPreD Consortium et al. (2024)
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results
Acta Oncol, 63, 379-384
DOI 10.2340/1651-226X.2024.28322, PubMed 38779911

Sorbye H, Hjortland GO, Vestermark LW, Sundlov A, Assmus J, Couvelard A, Perren A, Langer SW (2024)
NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 36 (11), e13428
DOI 10.1111/jne.13428, PubMed 38937137

Ullern A, Holm K, Røssevold AH, Andresen NK, Bang C, Lingjærde OC, Naume B, Hov JR, Kyte JA (2024)
Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer
Mol Oncol, 19 (4), 1229-1243
DOI 10.1002/1878-0261.13760, PubMed 39545921

Willemsen M, Bulgarelli J, Chauhan SK, Lereim RR, Angeli D, Grisendi G, Krebbers G, Davidson I, Kyte JA, Guidoboni M, Luiten RM, Bakker WJ (2024)
Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy
Immunooncol Technol, 24, 101009
DOI 10.1016/j.iotech.2024.101009, PubMed 39697983

Publications 2023

Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dréno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ (2023)
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
J Clin Oncol, 41 (15), 2724-2735
DOI 10.1200/JCO.22.02072, PubMed 36780608

Baech J, Husby S, Trab T, Kragholm K, Brown P, Gørløv JS, Jørgensen JM, Gudbrandsdottir S, Severinsen MT, Grønbaek K, Larsen TS, Wästerlid T, Eloranta S, Smeland KB, Jakobsen LH, El-Galaly TC (2023)
Cardiovascular diseases after high-dose chemotherapy and autologous stem cell transplant for lymphoma: A Danish population-based study
Br J Haematol, 204 (3), 967-975
DOI 10.1111/bjh.19272, PubMed 38155503

Beck C, Casey NP, Persiconi I, Moharrami NN, Sike A, Jin Y, Kyte JA (2023)
Development of a TGFβ-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy
Biomedicines, 11 (2)
DOI 10.3390/biomedicines11020459, PubMed 36830995

Dahl AA, Smeland KB, Eikeland S, Fagerli UM, Bersvendsen HS, Fosså A, Kiserud CE (2023)
Work ability and work status changes in long-term Hodgkin lymphoma survivors with focus on late adverse effects
J Cancer Surviv, 18 (6), 1921-1930
DOI 10.1007/s11764-023-01432-y, PubMed 37526861

Eikeland SA, Smeland KB, Simensen VC, Fagerli UM, Bersvendsen HS, Kiserud CE, Fosså A (2023)
Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment
Acta Oncol, 62 (1), 80-88
DOI 10.1080/0284186X.2023.2168215, PubMed 36715320

Elvebakken H, Hjortland GO, Garresori H, Andresen PA, Janssen EAM, Vintermyr OK, Lothe IMB, Sorbye H (2023)
Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 35 (4), e13256
DOI 10.1111/jne.13256, PubMed 37017614

Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Glimelius I, Marklund A, Larsen TS, Holte H, Fosså A, Smeland KB, El-Galaly TC, Eloranta S (2023)
Reproduction patterns among non-Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population-based matched cohort study
Br J Haematol, 202 (4), 785-795
DOI 10.1111/bjh.18938, PubMed 37325886

Entrop JP, Weibull CE, Smedby KE, Jakobsen LH, Øvlisen AK, Molin D, Glimelius I, Marklund A, Holte H, Fosså A, Smeland KB, El-Galaly TC, Eloranta S (2023)
Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway-A population-based matched cohort study
Int J Cancer, 153 (4), 723-731
DOI 10.1002/ijc.34552, PubMed 37119033

Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A (2023)
How I treat endocrine-dependent metastatic breast cancer
ESMO Open, 8 (2), 100882
DOI 10.1016/j.esmoop.2023.100882, PubMed 36806375

Gulbrandsen MS, Nøding AS, Smeland KB, Eikeland SA, Kiserud CE, Hjermstad MJ, Fosså A (2023)
Health-related quality of life, depressive symptoms, and chronic fatigue in long-term survivors of Hodgkin lymphoma
Leuk Lymphoma, 64 (6), 1139-1150
DOI 10.1080/10428194.2023.2198053, PubMed 37144290

Huuhtanen J, Kasanen H, Peltola K, Lönnberg T, Glumoff V, Brück O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Mäkelä S, Nyakas M, Li B, Hernberg M, Bono P, Lähdesmäki H, Kreutzman A, Mustjoki S (2023)
Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma
J Clin Invest, 133 (6)
DOI 10.1172/JCI164809, PubMed 36719749

Høland M, Berg KCG, Eilertsen IA, Bjerkehagen B, Kolberg M, Boye K, Lingjærde OC, Guren TK, Mandahl N, van den Berg E, Palmerini E, Smeland S, Picci P, Mertens F, Sveen A, Lothe RA (2023)
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
EBioMedicine, 97, 104829
DOI 10.1016/j.ebiom.2023.104829, PubMed 37837931

Jenul A, Stokmo HL, Schrunner S, Hjortland GO, Revheim ME, Tomic O (2023)
Novel ensemble feature selection techniques applied to high-grade gastroenteropancreatic neuroendocrine neoplasms for the prediction of survival
Comput Methods Programs Biomed, 244, 107934
DOI 10.1016/j.cmpb.2023.107934, PubMed 38016391

Knappskog S, Grob T, Venizelos A, Amstutz U, Hjortland GO, Lothe IM, Kersten C, Hofsli E, Sundlöv A, Elvebakken H, Garresori H, Couvelard A, Svensson J, Sorbye H, Perren A (2023)
Mutation Spectrum in Liquid Versus Solid Biopsies From Patients With Advanced Gastroenteropancreatic Neuroendocrine Carcinoma
JCO Precis Oncol, 7, e2200336
DOI 10.1200/PO.22.00336, PubMed 36753687

Morken S, Langer SW, Sundlöv A, Vestermark LW, Ladekarl M, Hjortland GO, Svensson JB, Tabaksblat EM, Haslerud TM, Assmus J, Detlefsen S, Couvelard A, Perren A, Sorbye H (2023)
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
Br J Cancer, 129 (12), 1930-1939
DOI 10.1038/s41416-023-02462-0, PubMed 37872405

Nilsson K, Klevebro F, Sunde B, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, Alexandersson von Döbeln G, Hjortland GO, Wang N, Shang Y, Borg D, Quaas A, Bartella I, Bruns C, Schröder W, Nilsson M (2023)
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial
Ann Oncol, 34 (11), 1015-1024
DOI 10.1016/j.annonc.2023.08.010, PubMed 37657554

Oh DY, Algazi A, Capdevila J, Longo F, Miller W, Chun Bing JT, Bonilla CE, Chung HC, Guren TK, Lin CC, Motola-Kuba D, Shah M, Hadoux J, Yao L, Jin F, Norwood K, Lebellec L (2023)
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
Cancer, 129 (8), 1195-1204
DOI 10.1002/cncr.34657, PubMed 36748723

Piperno-Neumann S, Carlino MS, Boni V, Loirat D, Speetjens FM, Park JJ, Calvo E, Carvajal RD, Nyakas M, Gonzalez-Maffe J, Zhu X, Shirley MD, Ramkumar T, Fessehatsion A, Burks HE, Yerramilli-Rao P, Kapiteijn E (2023)
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
Br J Cancer, 128 (6), 1040-1051
DOI 10.1038/s41416-022-02133-6, PubMed 36624219

Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, Nyakas M, Kee D, Petrella TM, Blaustein A, Lotem M, Arance A, Daud AI, Hamid O, Larkin J, Anderson J, Krepler C, Grebennik D, Long GV (2023)
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
J Clin Oncol, 41 (24), 3998-4003
DOI 10.1200/JCO.22.01599, PubMed 37348035

Shoushtari AN, Olszanski AJ, Nyakas M, Hornyak TJ, Wolchok JD, Levitsky V, Kuryk L, Hansen TB, Jäderberg M (2023)
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma
Clin Cancer Res, 29 (1), 100-109
DOI 10.1158/1078-0432.CCR-22-2046, PubMed 36112545

Venizelos A, Sorbye H, Elvebakken H, Perren A, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Vestermark LW, Ladekarl M, Tabaksblat EM, Knappskog S (2023)
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 30 (10)
DOI 10.1530/ERC-23-0057, PubMed 37410378

Winge-Main A, Robsahm TE, Nyakas M, Festervoll G, Torkilseng E, Thybo S, Pati S, Carroll R (2023)
Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway
Future Oncol, 19 (3), 205-215
DOI 10.2217/fon-2022-0969, PubMed 36974621

Publications 2022

Callesen LB, Hamfjord J, Boysen AK, Pallisgaard N, Guren TK, Kure EH, Spindler KG (2022)
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Br J Cancer, 127 (3), 500-513
DOI 10.1038/s41416-022-01816-4, PubMed 35440666

Carlsson G, Koumarianou A, Guren TK, Haux J, Katsaounis P, Kentepozidis N, Pfeiffer P, Brændengen M, Mavroudis D, Taflin H, Skintemo L, Tell R, Papadimitriou C (2022)
A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
ESMO Open, 7 (5), 100589
DOI 10.1016/j.esmoop.2022.100589, PubMed 36183444

Dorraji E, Borgen E, Segura-Peña D, Rawat P, Smorodina E, Dunn C, Greiff V, Sekulić N, Russnes H, Kyte JA (2022)
Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform
Cancers (Basel), 14 (19)
DOI 10.3390/cancers14194859, PubMed 36230782

Eikeland SA, Smeland KB, Brekke M, Kiserud CE, Fosså A (2022)
Late-effect awareness and follow-up of cancer in general practice
Scand J Prim Health Care, 40 (3), 360-369
DOI 10.1080/02813432.2022.2139457, PubMed 36380478

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 225
DOI 10.1186/s12967-022-03432-5, PubMed 35568909

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022)
Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway
J Transl Med, 20 (1), 317
DOI 10.1186/s12967-022-03518-0, PubMed 35841045

Jin Y, Lorvik KB, Jin Y, Beck C, Sike A, Persiconi I, Kvaløy E, Saatcioglu F, Dunn C, Kyte JA (2022)
Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer
Mol Ther Oncolytics, 26, 189-206
DOI 10.1016/j.omto.2022.06.007, PubMed 35860008

Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J (2022)
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
ESMO Open, 7 (3), 100477
DOI 10.1016/j.esmoop.2022.100477, PubMed 35653981

Kryeziu K, Bergsland CH, Guren TK, Sveen A, Lothe RA (2022)
Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars
Biochim Biophys Acta Rev Cancer, 1877 (1), 188682
DOI 10.1016/j.bbcan.2022.188682, PubMed 35065193

Kyte JA (2022)
Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers
Cancers (Basel), 14 (3)
DOI 10.3390/cancers14030571, PubMed 35158839

Langen Stokmo H, Aly M, Bowitz Lothe IM, Borja AJ, Mehdizadeh Seraj S, Ghorpade R, Miao X, Hjortland GO, Malinen E, Sorbye H, Werner TJ, Alavi A, Revheim ME (2022)
Volumetric parameters from [¹⁸ F]FDG PET/CT predicts survival in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
J Neuroendocrinol, 34 (7), e13170
DOI 10.1111/jne.13170, PubMed 35729738

Marabelle A, Cassier PA, Fakih M, Kao S, Nielsen D, Italiano A, Guren TK, van Dongen MGJ, Spencer K, Bariani GM, Ascierto PA, Santoro A, Shah M, Asselah J, Iqbal S, Takahashi S, Piha-Paul SA, Ott PA, Chatterjee A, Jin F, Norwood K, Delord JP (2022)
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study
Lancet Gastroenterol Hepatol, 7 (5), 446-454
DOI 10.1016/S2468-1253(21)00382-4, PubMed 35114169

Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
AXL inhibition improves BRAF-targeted treatment in melanoma
Sci Rep, 12 (1), 5076
DOI 10.1038/s41598-022-09078-z, PubMed 35332208

Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA (2022)
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
Nat Med, 28 (12), 2573-2583
DOI 10.1038/s41591-022-02126-1, PubMed 36482103

Smedman TM, Guren TK, Tveit KM, Thomsen M, Andersen MH, Line PD, Dueland S (2022)
Health-Related Quality of Life in Colorectal Cancer Patients Treated With Liver Transplantation Compared to Chemotherapy
Transpl Int, 35, 10404
DOI 10.3389/ti.2022.10404, PubMed 35707633

Smeland K, Holte H, Fagerli UM, Bersvendsen H, Hjermstad MJ, Loge JH, Murbrach K, Linnsund MD, Fluge O, Stenehjem JS, Lund MB, Kvaloy S, Kiserud CE (2022)
Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life
Haematologica, 107 (11), 2698-2707
DOI 10.3324/haematol.2021.280413, PubMed 35484681

Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES, CONNECT Public–Private Partnership Consortium, Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R, InPreD-Norway and National Molecular Tumor Board Consortium, IMPRESS-Norway Consortium, Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å (2022)
A national precision cancer medicine implementation initiative for Norway
Nat Med, 28 (5), 885-887
DOI 10.1038/s41591-022-01777-4, PubMed 35513529

Aamdal E, Skovlund E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Hagene KT, Holmsen K, Aamdal S, Kaasa S, Guren TK, Kyte JA (2022)
Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
ESMO Open, 7 (5), 100588
DOI 10.1016/j.esmoop.2022.100588, PubMed 36116420

Publications 2021

Eikeland SA, Smeland KB, Mols F, Fagerli UM, Bersvendsen HS, Kiserud CE, Fosså A (2021)
Chemotherapy-induced peripheral neuropathy after modern treatment of Hodgkin's lymphoma; symptom burden and quality of life
Acta Oncol, 60 (7), 911-920
DOI 10.1080/0284186X.2021.1917776, PubMed 33905285

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Int J Cancer, 149 (6), 1385-1397
DOI 10.1002/ijc.33672, PubMed 33961700

Hamfjord J, Myklebust TÅ, Larsen IK, Kure EH, Glimelius B, Guren TK, Tveit KM, Guren MG (2021)
Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
Cancer Epidemiol Biomarkers Prev, 31 (2), 342-351
DOI 10.1158/1055-9965.EPI-21-0555, PubMed 34853022

Hernæs KH, Smeland KB, Fagerli UM, Kiserud CE (2021)
Post-treatment work patterns amongst survivors of lymphoma treated with high-dose chemotherapy with autologous stem-cell transplantation
BMC Cancer, 21 (1), 143
DOI 10.1186/s12885-021-07836-2, PubMed 33557789

Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK et al. (2021)
Burkitt Lymphoma International Prognostic Index
J Clin Oncol, 39 (10), 1129-1138
DOI 10.1200/JCO.20.03288, PubMed 33502927

Pommergaard HC, Nielsen K, Sorbye H, Federspiel B, Tabaksblat EM, Vestermark LW, Janson ET, Hansen CP, Ladekarl M, Garresori H, Hjortland GO, Sundlöv A, Galleberg R, Knigge P, Kjaer A, Langer SW, Knigge U (2021)
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms
J Neuroendocrinol, 33 (5), e12967
DOI 10.1111/jne.12967, PubMed 33769624

Ragnum HB, De Bortoli AM, Elsais A, Nilsen KB, Hammarstrom C, Nyakas M (2021)
A man in his sixties with dyspnoea following immunotherapy
Tidsskr. Nor. Laegeforen., 141 (12), 1190-1194

Ragnum HB, De Bortoli AM, Elsais A, Nilsen KB, Hammarström C, Nyakas M (2021)
A man in his sixties with dyspnoea following immunotherapy
Tidsskr Nor Laegeforen, 141 (2021-12)
DOI 10.4045/tidsskr.21.0139, PubMed 34505469

Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A (2021)
First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours
Br J Cancer, 126 (7), 1010-1017
DOI 10.1038/s41416-021-01657-7, PubMed 34903842

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
J Clin Oncol, 39 (4), 273-284
DOI 10.1200/JCO.20.02088, PubMed 33503393

Venizelos A, Elvebakken H, Perren A, Nikolaienko O, Deng W, Lothe IMB, Couvelard A, Hjortland GO, Sundlöv A, Svensson J, Garresori H, Kersten C, Hofsli E, Detlefsen S, Krogh M, Sorbye H, Knappskog S (2021)
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Endocr Relat Cancer, 29 (1), 1-14
DOI 10.1530/ERC-21-0152, PubMed 34647903

Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabrò L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL (2021)
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
Lancet Respir Med, 9 (6), 613-621
DOI 10.1016/S2213-2600(20)30515-4, PubMed 33836153

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
Front Immunol, 12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK (2021)
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up
Int J Cancer, 150 (1), 100-111
DOI 10.1002/ijc.33768, PubMed 34449877

Publications 2020

Ali AS, Langer SW, Federspiel B, Hjortland GO, Grønbæk H, Ladekarl M, Welin S, Weber Vestermark L, Arola J, Osterlund P, Knigge U, Sørbye H, Micke P, Grimelius L, Grönberg M, Tiensuu Janson E (2020)
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
PLoS One, 15 (12), e0243900
DOI 10.1371/journal.pone.0243900, PubMed 33315908

Ascierto PA, Del Vecchio M, Mackiewicz A, Robert C, Chiarion-Sileni V, Arance A, Lebbé C, Svane IM, McNeil C, Rutkowski P, Loquai C, Mortier L, Hamid O, Bastholt L, Dreno B, Schadendorf D, Garbe C, Nyakas M, Grob JJ, Thomas L, Liszkay G, Smylie M, Hoeller C, Ferraresi V, Grange F et al. (2020)
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
J Immunother Cancer, 8 (1)
DOI 10.1136/jitc-2019-000391, PubMed 32503946

Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Wilsgaard T, Smeland KB, Kiserud CE (2020)
Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress
Bone Marrow Transplant, 56 (4), 968-970
DOI 10.1038/s41409-020-01098-5, PubMed 33139869

Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, Sullivan RJ, Chiarion-Sileni V, Nyakas M, Kahler K, Hauschild A, Plummer R, Trojaniello C, Ascierto PA, Zimmer L, Schadendorf D, Allayous C, Lebbe C, Maurichi A, Santinami M, Roy S, Robert C, Lesimple T, Patel S, Versluis JM et al. (2020)
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Br J Cancer, 124 (3), 574-580
DOI 10.1038/s41416-020-01121-y, PubMed 33087895

Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397

Casey NP, Kyte JA, Fujiwara H (2020)
Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency
Methods Mol Biol, 2115, 327-349
DOI 10.1007/978-1-0716-0290-4_18, PubMed 32006409

Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
N Engl J Med, 383 (12), 1139-1148
DOI 10.1056/NEJMoa2005493, PubMed 32877599

Elvebakken H, Perren A, Scoazec JY, Tang LH, Federspiel B, Klimstra DS, Vestermark LW, Ali AS, Zlobec I, Myklebust TÅ, Hjortland GO, Langer SW, Gronbaek H, Knigge U, Tiensuu Janson E, Sorbye H (2020)
A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations
Neuroendocrinology, 111 (9), 883-894
DOI 10.1159/000511905, PubMed 33002892

Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM (2020)
Soluble AXL as a marker of disease progression and survival in melanoma
PLoS One, 15 (1), e0227187
DOI 10.1371/journal.pone.0227187, PubMed 31917795

Fosså A, Smeland KH, Fluge Ø, Tronstad KJ, Loge JH, Midttun Ø, Ueland PM, Kiserud CE (2020)
Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue
PLoS One, 15 (1), e0227384
DOI 10.1371/journal.pone.0227384, PubMed 31923274

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC (2020)
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Br J Haematol, 189 (4), 661-671
DOI 10.1111/bjh.16425, PubMed 32017050

Kyte JA, Andresen NK, Russnes HG, Fretland SØ, Falk RS, Lingjærde OC, Naume B (2020)
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163

Kyte JA, Røssevold A, Falk RS, Naume B (2020)
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer
J Transl Med, 18 (1), 252
DOI 10.1186/s12967-020-02424-7, PubMed 32576225

Nilsson K, Klevebro F, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, Hjortland GO, Bartella I, Schröder W, Bruns C, Nilsson M (2020)
Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Ann Surg, 272 (5), 684-689
DOI 10.1097/SLA.0000000000004340, PubMed 32833767

Ny L, Hernberg M, Nyakas M, Koivunen J, Oddershede L, Yoon M, Wang X, Guyot P, Geisler J (2020)
BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
Acta Oncol, 59 (7), 833-844
DOI 10.1080/0284186X.2020.1747636, PubMed 32285732

Puzanov I, Ribas A, Robert C, Schachter J, Nyakas M, Daud A, Arance A, Carlino MS, O'Day SJ, Long GV, Margolin KA, Dummer R, Schadendorf D, Lutzky J, Ascierto PA, Tarhini A, Lin J, Mogg R, Homet Moreno B, Ibrahim N, Hamid O (2020)
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
JAMA Oncol, 6 (8), 1256-1264
DOI 10.1001/jamaoncol.2020.2288, PubMed 32672795

Publications 2019

Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Seland M, Wilsgaard T, Smeland KB, Kiserud CE (2019)
Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation
Bone Marrow Transplant, 55 (5), 891-905
DOI 10.1038/s41409-019-0745-4, PubMed 31745250

Bersvendsen HS, Haugnes HS, Fagerli UM, Fluge Ø, Holte H, Smeland KB, Wilsgaard T, Kiserud CE (2019)
Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes
Acta Oncol, 58 (5), 690-699
DOI 10.1080/0284186X.2018.1558370, PubMed 30696346

Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown PN, Jakobsen LH, Frederiksen H, Jerkeman M, Fosså A, Andersson TML, Holte H, Bøgsted M, El-Galaly TC, Smedby KE (2019)
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study
J Clin Oncol, 37 (9), 703-713
DOI 10.1200/JCO.18.01652, PubMed 30726176

Fosså A, Smeland K, Fagerli UM, Galleberg RB, Bersvendsen HS, Holte H (2019)
Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016
Acta Oncol, 59 (1), 101-105
DOI 10.1080/0284186X.2019.1652765, PubMed 31429371

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Ann Oncol, 30 (7), 1088-1095
DOI 10.1093/annonc/mdz139, PubMed 31046124

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B (2019)
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Ann Oncol, 30 (7), 1154-1161
DOI 10.1093/annonc/mdz110, PubMed 30923820

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A et al. (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
N Engl J Med, 381 (17), 1632-1643
DOI 10.1056/NEJMoa1908075, PubMed 31566309

Kryeziu K, Bruun J, Guren TK, Sveen A, Lothe RA (2019)
Combination therapies with HSP90 inhibitors against colorectal cancer
Biochim Biophys Acta Rev Cancer, 1871 (2), 240-247
DOI 10.1016/j.bbcan.2019.01.002, PubMed 30708039

Kyte JA, Fåne A, Pule M, Gaudernack G (2019)
Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination
Oncoimmunology, 8 (4), e1565236
DOI 10.1080/2162402X.2019.1565236, PubMed 30906659

Long GV, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Hauschild A (2019)
Reply to E. Hindié and K.R. Hess
J Clin Oncol, 37 (15), 1356-1358
DOI 10.1200/JCO.19.00004, PubMed 30939092

Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R et al. (2019)
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
Eur J Cancer, 119, 168-178
DOI 10.1016/j.ejca.2019.07.010, PubMed 31445199

Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, Aukrust P, Maelandsmo GM, Ueland T (2019)
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848

Schadendorf D, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, Mandala M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R et al. (2019)
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)
Eur J Cancer, 121, 144-153
DOI 10.1016/j.ejca.2019.08.014, PubMed 31581055

Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM, Long GV (2019)
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF^V600E or BRAF^V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Lancet Oncol, 20 (5), 701-710
DOI 10.1016/S1470-2045(18)30940-9, PubMed 30928620

Simensen VC, Smeland KB, Kiserud CE, Dahl AA, Bersvendsen HS, Fluge Ø, Fagerli UM, Fosså A (2019)
Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma
Acta Oncol, 58 (9), 1315-1322
DOI 10.1080/0284186X.2019.1637538, PubMed 31286808

Smedman TM, Guren TK, Line PD, Dueland S (2019)
Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study
Transpl Int, 32 (11), 1144-1150
DOI 10.1111/tri.13471, PubMed 31209941

Tekpli X, Lien T, Røssevold AH, Nebdal D, Borgen E, Ohnstad HO, Kyte JA, Vallon-Christersson J, Fongaard M, Due EU, Svartdal LG, Sveli MAT, Garred Ø, OSBREAC, Frigessi A, Sahlberg KK, Sørlie T, Russnes HG, Naume B, Kristensen VN (2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
Nat Commun, 10 (1), 5499
DOI 10.1038/s41467-019-13329-5, PubMed 31796750

Publications 2018

Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET (2018)
Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Med Oncol, 35 (4), 47
DOI 10.1007/s12032-018-1103-x, PubMed 29511910

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, Nyakas M, Caglevic C, Tarhini A, Blank C, Hoeller C, Bar-Sela G, Barrow C, Wolter P, Zhou H, Emancipator K, Jensen EH, Ebbinghaus S, Ibrahim N, Daud A (2018)
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Eur J Cancer, 101, 236-243
DOI 10.1016/j.ejca.2018.06.034, PubMed 30096704

Claassen YHM, Bastiaannet E, Hartgrink HH, Dikken JL, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Schutter H, Lindblad M, Hedberg J, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Koessler T, Chevallay M, Allum WH, van de Velde CJH (2018)
International comparison of treatment strategy and survival in metastatic gastric cancer
BJS Open, 3 (1), 56-61
DOI 10.1002/bjs5.103, PubMed 30734016

Claassen YHM, Dikken JL, Hartgrink HH, de Steur WO, Slingerland M, Verhoeven RHA, van Eycken E, de Schutter H, Johansson J, Rouvelas I, Johnson E, Hjortland GO, Jensen LS, Larsson HJ, Allum WH, Portielje JEA, Bastiaannet E, van de Velde CJH (2018)
North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis
Eur J Surg Oncol, 44 (12), 1982-1989
DOI 10.1016/j.ejso.2018.09.014, PubMed 30343998

Eide HA, Knudtsen IS, Sandhu V, Løndalen AM, Halvorsen AR, Abravan A, Kure EH, Bogsrud TV, Brustugun OT, Kyte JA, Malinen E, Helland Å (2018)
Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy
Adv Radiat Oncol, 3 (2), 130-138
DOI 10.1016/j.adro.2017.12.007, PubMed 29904737

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV (2018)
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
J Clin Oncol, 36 (35), 3441-3449
DOI 10.1200/JCO.18.01219, PubMed 30343620

Jabeen S, Espinoza JA, Torland LA, Zucknick M, Kumar S, Haakensen VD, Lüders T, Engebraaten O, Børresen-Dale AL, Kyte JA, Gromov P, Naume B, Kristensen V, Gromova I, Tekpli X (2018)
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics
Oncoimmunology, 8 (2), e1537691
DOI 10.1080/2162402X.2018.1537691, PubMed 30713794

Jabeen S, Zucknick M, Nome M, Dannenfelser R, Fleischer T, Kumar S, Lüders T, von der Lippe Gythfeldt H, Troyanskaya O, Kyte JA, Børresen-Dale AL, Naume B, Tekpli X, Engebraaten O, Kristensen V (2018)
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
Oncoimmunology, 7 (11), e1457598
DOI 10.1080/2162402X.2018.1457598, PubMed 30377556

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W, Donica M, Makrutzki M, Blank C (2018)
An open-label, multicentre safety study of vemurafenib in patients with BRAF^V600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
Eur J Cancer, 107, 175-185
DOI 10.1016/j.ejca.2018.11.018, PubMed 30580112

Oei VYS, Siernicka M, Graczyk-Jarzynka A, Hoel HJ, Yang W, Palacios D, Almåsbak H, Bajor M, Clement D, Brandt L, Önfelt B, Goodridge J, Winiarska M, Zagozdzon R, Olweus J, Kyte JA, Malmberg KJ (2018)
Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
Cancer Immunol Res, 6 (4), 467-480
DOI 10.1158/2326-6066.CIR-17-0207, PubMed 29459477

Smedman TM, Line PD, Guren TK, Dueland S (2018)
Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients
Acta Oncol, 57 (10), 1414-1418
DOI 10.1080/0284186X.2018.1479069, PubMed 29912605

Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Holte H, Lund MB, Murbræch K, Reinertsen KV, Stenehjem JS, Kiserud CE (2018)
Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity
Bone Marrow Transplant, 54 (4), 607-610
DOI 10.1038/s41409-018-0342-y, PubMed 30262906

Thomsen M, Skovlund E, Sorbye H, Bolstad N, Nustad KJ, Glimelius B, Pfeiffer P, Kure EH, Johansen JS, Tveit KM, Christoffersen T, Guren TK (2018)
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome
Br J Cancer, 118 (12), 1609-1616
DOI 10.1038/s41416-018-0115-9, PubMed 29872151

Publications 2017

Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET (2017)
Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma
PLoS One, 12 (11), e0187667
DOI 10.1371/journal.pone.0187667, PubMed 29112960

Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D et al. (2017)
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Lancet Oncol, 18 (5), 611-622
DOI 10.1016/S1470-2045(17)30231-0, PubMed 28359784

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R (2017)
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Clin Cancer Res, 23 (18), 5339-5348
DOI 10.1158/1078-0432.CCR-16-2923, PubMed 28611198

Dueland S, Guren TK, Boberg KM, Reims HM, Grzyb K, Aamdal S, Julsrud L, Line PD (2017)
Acute liver graft rejection after ipilimumab therapy
Ann Oncol, 28 (10), 2619-2620
DOI 10.1093/annonc/mdx281, PubMed 28961840

Galleberg RB, Knigge U, Tiensuu Janson E, Vestermark LW, Haugvik SP, Ladekarl M, Langer SW, Grønbæk H, Österlund P, Hjortland GO, Assmus J, Tang L, Perren A, Sorbye H (2017)
Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas
Eur J Surg Oncol, 43 (9), 1682-1689
DOI 10.1016/j.ejso.2017.04.010, PubMed 28522174

Guren TK, Thomsen M, Kure EH, Sorbye H, Glimelius B, Pfeiffer P, Österlund P, Sigurdsson F, Lothe IMB, Dalsgaard AM, Skovlund E, Christoffersen T, Tveit KM (2017)
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study
Br J Cancer, 116 (10), 1271-1278
DOI 10.1038/bjc.2017.93, PubMed 28399112

Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
N Engl J Med, 377 (19), 1813-1823
DOI 10.1056/NEJMoa1708539, PubMed 28891408

Mezheyeuski A, Strell C, Hrynchyk I, Guren TK, Dragomir A, Doroshenko T, Pashkova O, Gorgun J, Ruksha K, Pfeiffer P, Kure EH, Sorbye H, Edler D, Martling A, Glimelius B, Östman A, Portyanko A (2017)
Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer
Virchows Arch, 472 (3), 395-405
DOI 10.1007/s00428-017-2263-3, PubMed 29134439

Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Sveli MAT, Kyte JA, Kristensen VN, Geitvik GA, Schlichting E, Wist EA, Sørlie T, Russnes HG, Naume B (2017)
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
Breast Cancer Res, 19 (1), 120
DOI 10.1186/s13058-017-0911-9, PubMed 29137653

Seland M, Smeland KB, Bjøro T, Falk RS, Fosså SD, Gjesdal CG, Godang K, Holte H, Svartberg J, Syversen U, Bollerslev J, Kiserud CE (2017)
Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation
Acta Oncol, 56 (4), 590-598
DOI 10.1080/0284186X.2016.1267870, PubMed 28077016

Smeland KH (2017)
[Not Available]
Tidsskr Nor Laegeforen, 137 (6), 470
DOI 10.4045/tidsskr.16.1111, PubMed 28332807

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy SO, Wethal T, Kiserud CE, Samersaw-Lund MB (2017)
Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
Acta Oncol, 57 (6), 773-781
DOI 10.1080/0284186X.2017.1406137, PubMed 29171324

Thomsen M, Guren MG, Skovlund E, Glimelius B, Hjermstad MJ, Johansen JS, Kure E, Sorbye H, Pfeiffer P, Christoffersen T, Guren TK, Tveit KM (2017)
Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status
Eur J Cancer, 81, 26-35
DOI 10.1016/j.ejca.2017.04.026, PubMed 28595137

Ødegård J, Sondresen JE, Aasrum M, Tveteraas IH, Guren TK, Christoffersen T, Thoresen GH (2017)
Differential effects of epidermal growth factor (EGF) receptor ligands on receptor binding, downstream signalling pathways and DNA synthesis in hepatocytes
Growth Factors, 35 (6), 239-248
DOI 10.1080/08977194.2018.1453506, PubMed 29582692

Publications 2016

Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A (2016)
Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation
Ecancermedicalscience, 10, 691
DOI 10.3332/ecancer.2016.691, PubMed 27994647

Eide HA, Halvorsen AR, Sandhu V, Fåne A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, Helland Å (2016)
Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease
Clin Transl Immunology, 5 (11), e109
DOI 10.1038/cti.2016.65, PubMed 27990285

Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, Holte H, Dahl AA (2016)
Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation
Acta Oncol, 55 (5), 547-53
DOI 10.3109/0284186X.2015.1125015, PubMed 27123741

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
Oncoimmunology, 5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886

Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
Oncoimmunology, 5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747

Mezheyeuski A, Bradic Lindh M, Guren TK, Dragomir A, Pfeiffer P, Kure EH, Ikdahl T, Skovlund E, Corvigno S, Strell C, Pietras K, Ponten F, Mulder J, Qvortrup C, Portyanko A, Tveit KM, Glimelius B, Sorbye H, Östman A (2016)
Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer
Oncotarget, 7 (27), 41948-41958
DOI 10.18632/oncotarget.9632, PubMed 27248825

Murbraech K, Holte E, Broch K, Smeland KB, Holte H, Rösner A, Lund MB, Dalen H, Kiserud C, Aakhus S (2016)
Impaired Right Ventricular Function in Long-Term Lymphoma Survivors
J Am Soc Echocardiogr, 29 (6), 528-36
DOI 10.1016/j.echo.2016.02.014, PubMed 27038515

Murbraech K, Wethal T, Smeland KB, Holte H, Loge JH, Holte E, Rösner A, Dalen H, Kiserud CE, Aakhus S (2016)
Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study
JACC Cardiovasc Imaging, 9 (3), 230-9
DOI 10.1016/j.jcmg.2015.06.028, PubMed 26897666

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frodin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Watkins DJ (2016)
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial
Int J Cancer, 140 (2), 431-439
DOI 10.1002/ijc.30453, PubMed 27681944

Sioud M, Nyakas M, Sæbøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G (2016)
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
DOI 10.1155/2016/9639585, PubMed 27504122

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Thorsen L, Arbo I, Jones LW, Aakhus S, Lund MB, Kiserud CE (2016)
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation
Br J Cancer, 115 (2), 178-87
DOI 10.1038/bjc.2016.180, PubMed 27351215

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Wethal T, Kiserud CE, Lund MB (2016)
Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
Bone Marrow Transplant, 52 (4), 646-649
DOI 10.1038/bmt.2016.338, PubMed 27991891

Tarpgaard LS, Ørum-Madsen MS, Christensen IJ, Nordgaard C, Noer J, Guren TK, Glimelius B, Sorbye H, Ikdahl T, Kure EH, Tveit KM, Nielsen HJ, Pfeiffer P, Brünner N, Moreira JM (2016)
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer
Oncotarget, 7 (37), 59441-59457
DOI 10.18632/oncotarget.11118, PubMed 27509063

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016)
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
Oncotarget, 7 (46), 75013-75022
DOI 10.18632/oncotarget.12601, PubMed 27738330

Publications 2015

Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther, 22 (5), 391-403
DOI 10.1038/gt.2015.4, PubMed 25652098

Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, Foss A, Tveit KM (2015)
Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?
Ann Surg, 261 (5), 956-60
DOI 10.1097/SLA.0000000000000786, PubMed 24950280

Hansen GL, Gaudernack G, Brunsvig PF, Cvancarova M, Kyte JA (2015)
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
Cancer Immunol Immunother, 64 (12), 1609-21
DOI 10.1007/s00262-015-1766-5, PubMed 26498005

Murbraech K, Smeland KB, Holte H, Loge JH, Lund MB, Wethal T, Holte E, Rösner A, Dalen H, Kvaløy S, Falk RS, Aakhus S, Kiserud CE (2015)
Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study
J Clin Oncol, 33 (24), 2683-91
DOI 10.1200/JCO.2015.60.8125, PubMed 26169610

Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ (2015)
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer
J Natl Cancer Inst, 107 (12), djv258
DOI 10.1093/jnci/djv258, PubMed 26405092

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H (2015)
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Haematologica, 100 (6), e240-3
DOI 10.3324/haematol.2014.119214, PubMed 25682605

Tarpgaard LS, Christensen IJ, Høyer-Hansen G, Lund IK, Guren TK, Glimelius B, Sorbye H, Tveit KM, Nielsen HJ, Moreira JM, Pfeiffer P, Brünner N (2015)
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab
Int J Cancer, 137 (10), 2470-7
DOI 10.1002/ijc.29476, PubMed 25664394

Publications 2014

Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA (2014)
Portrait of the PI3K/AKT pathway in colorectal cancer
Biochim Biophys Acta, 1855 (1), 104-21
DOI 10.1016/j.bbcan.2014.09.008, PubMed 25450577

Dueland S, Hagness M, Line PD, Guren TK, Tveit KM, Foss A (2014)
Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?
Ann Surg Oncol, 22 (7), 2195-200
DOI 10.1245/s10434-014-4137-0, PubMed 25297902

Gjersvik P, Kyte JA (2014)
[Field cancerization of skin and mucous membranes]
Tidsskr Nor Laegeforen, 134 (18), 1769
DOI 10.4045/tidsskr.13.1454, PubMed 25273254

Skrbo N, Hjortland GO, Kristian A, Holm R, Nord S, Prasmickaite L, Engebraaten O, Mælandsmo GM, Sørlie T, Andersen K (2014)
Differential in vivo tumorigenicity of distinct subpopulations from a luminal-like breast cancer xenograft
PLoS One, 9 (11), e113278
DOI 10.1371/journal.pone.0113278, PubMed 25419568

Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM (2014)
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
PLoS One, 9 (2), e87746
DOI 10.1371/journal.pone.0087746, PubMed 24498368

Publications 2013

Cohen RB, Aamdal S, Nyakas M, Cavallin M, Green D, Learoyd M, Smith I, Kurzrock R (2013)
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
Eur J Cancer, 49 (7), 1521-9
DOI 10.1016/j.ejca.2013.01.013, PubMed 23433846

del Campo AB, Kyte JA, Carretero J, Zinchencko S, Méndez R, González-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernack G, Garrido F, Aptsiauri N (2013)
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Int J Cancer, 134 (1), 102-13
DOI 10.1002/ijc.28338, PubMed 23784959

Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S, Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA (2013)
Malignant melanoma--diagnosis, treatment and follow-up in Norway
Tidsskr Nor Laegeforen, 133 (20), 2154-9
DOI 10.4045/tidsskr.12.1416, PubMed 24172628

Kyte JA (2013)
[The cancer riddle is outdated]
Tidsskr Nor Laegeforen, 133 (18), 1907
DOI 10.4045/tidsskr.13.1037, PubMed 24084948

Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR (2013)
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Lancet Oncol, 14 (8), 733-40
DOI 10.1016/S1470-2045(13)70237-7, PubMed 23735514

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S (2013)
High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment
Tidsskr Nor Laegeforen, 133 (16), 1735-9
DOI 10.4045/tidsskr.13.0319, PubMed 24005713

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Cancer Immunol Immunother, 62 (9), 1499-509
DOI 10.1007/s00262-013-1453-3, PubMed 23817721

Publications 2012

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D et al. (2012)
Improved survival with MEK inhibition in BRAF-mutated melanoma
N Engl J Med, 367 (2), 107-14
DOI 10.1056/NEJMoa1203421, PubMed 22663011

Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E (2012)
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
DOI 10.1038/bjc.2012.158, PubMed 22531637

Publications 2011

Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169

Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
BMC Cancer, 11, 455
DOI 10.1186/1471-2407-11-455, PubMed 22014070

Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
Clin Cancer Res, 17 (13), 4568-80
DOI 10.1158/1078-0432.CCR-11-0184, PubMed 21586625

Publications 2010

Kyte JA (2010)
Third International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD 2009)
Expert Rev Vaccines, 9 (2), 119-23
DOI 10.1586/erv.09.157, PubMed 20109021

Kyte JA (2010)
[We know more than we can understand]
Tidsskr Nor Laegeforen, 130 (22), 2217
DOI 10.4045/tidsskr.10.1000, PubMed 21109831

Publications 2009

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
Mol Oncol, 3 (5-6), 469-82
DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161

Christoffersen T, Guren TK, Spindler KL, Dahl O, Lønning PE, Gjertsen BT (2009)
Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues
Eur J Pharmacol, 625 (1-3), 6-22
DOI 10.1016/j.ejphar.2009.10.009, PubMed 19836383

Kyte JA (2009)
Cancer vaccination with telomerase peptide GV1001
Expert Opin Investig Drugs, 18 (5), 687-94
DOI 10.1517/13543780902897631, PubMed 19388882

Kyte JA (2009)
[Nobel Prize for mitotic clock]
Tidsskr Nor Laegeforen, 129 (23), 2470
DOI 10.4045/tidsskr.09.1298, PubMed 19997132

Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G (2009)
Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination
Cancer Immunol Immunother, 58 (10), 1609-26
DOI 10.1007/s00262-009-0670-2, PubMed 19221745

Publications 2008

Dajani OF, Meisdalen K, Guren TK, Aasrum M, Tveteraas IH, Lilleby P, Thoresen GH, Sandnes D, Christoffersen T (2008)
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes
J Cell Physiol, 214 (2), 371-80
DOI 10.1002/jcp.21205, PubMed 17654493

Publications 2006

Kyte JA (2006)
[Cancer vaccines]
Tidsskr Nor Laegeforen, 126 (22), 2969-73
PubMed 17117197

Kyte JA, Gaudernack G (2006)
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
Cancer Immunol Immunother, 55 (11), 1432-42
DOI 10.1007/s00262-006-0161-7, PubMed 16612595

Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2006)
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Cancer Immunol Immunother, 56 (5), 659-75
DOI 10.1007/s00262-006-0222-y, PubMed 16947019

Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
Cancer Gene Ther, 13 (10), 905-18
DOI 10.1038/sj.cgt.7700961, PubMed 16710345

Publications 2005

Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM (2005)
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen, 125 (22), 3115-9
PubMed 16299568

Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G (2005)
Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
Cancer Gene Ther, 12 (6), 579-91
DOI 10.1038/sj.cgt.7700837, PubMed 15818380

Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G (2005)
Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
Br J Cancer, 93 (7), 749-56
DOI 10.1038/sj.bjc.6602761, PubMed 16136047

Publications 2004

Hjortland GO, Garman-Vik SS, Juell S, Olsen OE, Hirschberg H, Fodstad O, Engebraaten O (2004)
Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme
J Neurosurg, 100 (2), 320-7
DOI 10.3171/jns.2004.100.2.0320, PubMed 15086240

Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, Hirschberg H, Fodstad Ø, Engebraaten O (2004)
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells
Exp Cell Res, 294 (1), 130-9
DOI 10.1016/j.yexcr.2003.10.013, PubMed 14980508

Uzdensky AB, Juzeniene A, Kolpakova E, Hjortland GO, Juzenas P, Moan J (2004)
Photosensitization with protoporphyrin IX inhibits attachment of cancer cells to a substratum
Biochem Biophys Res Commun, 322 (2), 452-7
DOI 10.1016/j.bbrc.2004.07.132, PubMed 15325251

Publications 2003

Guren TK, Ødegård J, Abrahamsen H, Thoresen GH, Susa M, Andersson Y, Østby E, Christoffersen T (2003)
EGF receptor-mediated, c-Src-dependent, activation of Stat5b is downregulated in mitogenically responsive hepatocytes
J Cell Physiol, 196 (1), 113-23
DOI 10.1002/jcp.10282, PubMed 12767047

Hjortland GO, Bjørnland K, Pettersen S, Garman-Vik SS, Emilsen E, Nesland JM, Fodstad O, Engebraaten O (2003)
Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1
Clin Exp Metastasis, 20 (4), 301-9
DOI 10.1023/a:1024040718238, PubMed 12856717

Thoresen GH, Guren TK, Christoffersen T (2003)
Role of ERK, p38 and PI3-kinase in EGF receptor-mediated mitogenic signalling in cultured rat hepatocytes: requirement for sustained ERK activation
Cell Physiol Biochem, 13 (4), 229-38
DOI 10.1159/000072426, PubMed 12876381

Publications 2002

Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O (2002)
Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals
Int J Cancer, 97 (6), 846-52
DOI 10.1002/ijc.10137, PubMed 11857366

Friesen SA, Hjortland GO, Madsen SJ, Hirschberg H, Engebraten O, Nesland JM, Peng Q (2002)
5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review)
Int J Oncol, 21 (3), 577-82
PubMed 12168102

Publications 2001

Uzdensky AB, Ma LW, Iani V, Hjortland GO, Steen HB, Moan J (2001)
Intracellular localisation of hypericin in human glioblastoma and carcinoma cell lines
Lasers Med Sci, 16 (4), 276-83
DOI 10.1007/pl00011364, PubMed 11702633

Publications 2000

Skarpen E, Lindeman B, Thoresen GH, Guren TK, Oksvold MP, Christoffersen T, Huitfeldt HS (2000)
Impaired nuclear accumulation and shortened phosphorylation of ERK after growth factor stimulation in cultured hepatocytes from rats exposed to 2-acetylaminofluorene
Mol Carcinog, 28 (2), 84-96
DOI 10.1002/1098-2744(200006)28:2<84::aid-mc4>3.0.co;2-x, PubMed 10900465

Publications 1999

Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O (1999)
Growth of precultured human glioma specimens in nude rat brain
J Neurosurg, 90 (1), 125-32
DOI 10.3171/jns.1999.90.1.0125, PubMed 10413165

Guren TK, Abrahamsen H, Thoresen GH, Babaie E, Berg T, Christoffersen T (1999)
EGF-induced activation of Stat1, Stat3, and Stat5b is unrelated to the stimulation of DNA synthesis in cultured hepatocytes
Biochem Biophys Res Commun, 258 (3), 565-71
DOI 10.1006/bbrc.1999.0684, PubMed 10329425

Munthe LA, Kyte JA, Bogen B (1999)
Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo
Eur J Immunol, 29 (12), 4043-52
DOI 10.1002/(SICI)1521-4141(199912)29:12<4043::AID-IMMU4043>3.0.CO;2-E, PubMed 10602015

Publications 1998

Skarpen E, Johannessen LE, Bjerk K, Fasteng H, Guren TK, Lindeman B, Thoresen GH, Christoffersen T, Stang E, Huitfeldt HS, Madshus IH (1998)
Endocytosed epidermal growth factor (EGF) receptors contribute to the EGF-mediated growth arrest in A431 cells by inducing a sustained increase in p21/CIP1
Exp Cell Res, 243 (1), 161-72
DOI 10.1006/excr.1998.4127, PubMed 9716460

Thoresen GH, Guren TK, Sandnes D, Peak M, Agius L, Christoffersen T (1998)
Response to transforming growth factor alpha (TGFalpha) and epidermal growth factor (EGF) in hepatocytes: lower EGF receptor affinity of TGFalpha is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis
J Cell Physiol, 175 (1), 10-8
DOI 10.1002/(SICI)1097-4652(199804)175:1<10::AID-JCP2>3.0.CO;2-F, PubMed 9491776

Publications 1996

Guren TK, Thoresen GH, Dajani OF, Taraldsrud E, Moberg ER, Christoffersen T (1996)
Epidermal growth factor behaves as a partial agonist in hepatocytes: effects on DNA synthesis in primary culture and competition with transforming growth factor alpha
Growth Factors, 13 (3-4), 171-9
DOI 10.3109/08977199609003219, PubMed 8919025

Publications 1994

Dajani OF, Refsnes M, Guren TK, Horn RS, Thoresen GH, Christoffersen T (1994)
Elevated glucose concentrations inhibit DNA synthesis and expression of c-myc in cultured hepatocytes
Biochem Biophys Res Commun, 202 (3), 1476-82
DOI 10.1006/bbrc.1994.2097, PubMed 8060330

Publications 1990

Thoresen GH, Sand TE, Refsnes M, Dajani OF, Guren TK, Gladhaug IP, Killi A, Christoffersen T (1990)
Dual effects of glucagon and cyclic AMP on DNA synthesis in cultured rat hepatocytes: stimulatory regulation in early G1 and inhibition shortly before the S phase entry
J Cell Physiol, 144 (3), 523-30
DOI 10.1002/jcp.1041440321, PubMed 2167904